LAS VEGAS, Oct. 28, 2019 /PRNewswire/ — AEVOLVE, a medical innovation platform, is a platinum sponsor of the second annual World Crypto Conference (WCC), which will attract thousands of digital currency and blockchain technology enthusiasts to the Las Vegas strip October 29 through 31, 2019.
In recent years, there has been some good news for many of the 30 million people in the U.S. diagnosed with a rare disease, in the form of long-awaited treatment for a number of specific conditions — but this progress has come at a staggering cost for these prescription medications. Fortunately, a new company focusing on life sciences — AEVOLVE AG — has a plan to support medical research that will benefit millions of others with rare diseases, without the alarming costs that are currently associated with drugs of this kind.
Burdened by declining productivity and innovation, biopharma is seeking new ways of financing its growing needs. According to the Tufts Center for the study of Drug Development (CSDD), the cost to develop a new prescription drug is pegged at $2.6 billion. This marks a 145% increase from 2003 estimates, according to an article republished on Scientific American.
Rogelio Santos, Jr., CEO of Aevolve, a new platform dedicated to supporting innovative medical research, recently commented on the disturbing gap that exists between the millions of people who have been diagnosed with a rare disease and the life-saving medical treatment they are currently lacking. “Shockingly, 95% of all rare diseases today have absolutely no treatment.
No definite cure exists for Alzheimer’s disease yet, but promising drugs have emerged through the years that help stem its progress. However, these treatments must be administered early in the course of the illness for them to do any good. This race against time has pushed researchers to find other ways to tame this debilitating disease.
(Zug, SWITZERLAND — September 12, 2019) AEVOLVE AG, www.aevolve.health, a blockchain-powered biomedical financing engine, reiterated its commitment to supporting Alzheimer’s disease related research at the beginning of September, which is World Alzheimer’s Month.
As countries celebrate World Alzheimer’s Month and World Alzheimer’s Day in September, the international campaign to raise awareness and challenge the stigma that surrounds dementia continues to intensify.
Mr. Vonz Santos, the owner of biotech company, Amylex, introduces an innovation in the search for the cure to Alzheimer’s disease. He explains the process of intervening in the pathological process of beta Amyloids in the body to prevent them from becoming deadly.
